lomustine

As a result, three repurposed drugs were identified as priorities: (i) mefloquine (reference drug: vorasidenib citrate), (ii) clofibric acid (reference drug: carmustine), and armillarisin A (reference drug: lomustine). These results also suggest repurposing candidates for synergistic combinations across different brain tumors. The two applications developed in this work are freely accessible and in the public domain at https://assay.smallmoles.com/escorwin.

P3, N=225, Recruiting, Children's Oncology Group | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Dec 2027 --> Dec 2029

P2/3, N=30, Not yet recruiting, Telix Pharmaceuticals (Innovations) Pty Limited

P3, N=265, Active, not recruiting, NRG Oncology | Suspended --> Active, not recruiting

P2, N=45, Active, not recruiting, Children's Oncology Group | Trial completion date: Jun 2027 --> Mar 2028 | Trial primary completion date: Jun 2027 --> Mar 2028

Here the authors report the effects of the off-label use of ivosidenib. The INDIGO trial published evidence of efficacy in using an IDH inhibitor for low-grade gliomas. The role of these drugs in high-grade IDH-mutant gliomas is currently unknown. Further studies are needed to assess their impact on overall and progression-free survival. https://thejns.org/doi/10.3171/CASE25572.

In this discourse, we delineate the case of a 42-year-old male patient diagnosed with IDH-wild-type, MGMT-unmethylated, TERT promoter-mutated, and EGFR-amplified GBM, who manifested an early recurrence during adjuvant temozolomide therapy. Our findings, contextualized within contemporary evidence on re-irradiation (stereotactic radiosurgery/fractionated stereotactic radiation therapy) and combinatorial strategies (BEV with lomustine or irinotecan), underscore the need for further empirical investigation to optimize treatment sequencing in r-GBM. This case emphasizes the necessity for individualized multimodal approaches to improve outcomes in this refractory patient population.

Here, we report atypical clinicopathological features observed in the case of CEL. These findings have potential biological, diagnostic, and prognostic relevance, emphasizing the need for further studies to elucidate their clinical significance and to expand the understanding of this disease.

P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2031 --> Mar 2033 | Trial primary completion date: Mar 2031 --> Mar 2033

P3, N=306, Suspended, NRG Oncology | Recruiting --> Suspended

The patient underwent surgical excision via enterectomy, followed by adjuvant lomustine chemotherapy, achieving complete remission. Despite transient chemotherapy-induced myelosuppression, the cat remains alive and disease-free 2 years after diagnosis. This case highlights the importance of combining imaging, histopathology, and IHC when diagnosing feline intestinal masses.

Chemotherapy with l-asparaginase, vincristine, cyclophosphamide, doxorubicin and prednisone was initiated; however, neurological symptoms developed after the first cycle. Subsequent cerebrospinal fluid cytology and flow cytometry suggested central nervous system involvement in the lymphoma, and the dog was euthanized owing to disease progression despite the addition of lomustine. To our knowledge, this is the first report of bilateral retrobulbar large B-cell lymphoma with multifocal involvement in a dog. A comprehensive assessment of diagnostic modalities is essential to diagnose extranodal lymphoma and assess extranodal involvement.